文献速递肝病

肝硬化与SARS-CoV-2感染:美国退伍军人感染、住院、通气及死亡风险

Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.
PubMed 文献 · Hepatology · 2021-06-02

基于美国退伍军人健康系统88,747例SARS-CoV-2检测者,肝硬化患者检测阳性率低于无肝硬化者(8.5% vs 11.5%)。肝硬化合并感染者的30天死亡率和通气率最高(17.1%和13.0%)。肝硬化患者感染后死亡风险增加3.5倍,感染患者中肝硬化增加死亡风险1.7倍。

要点

  • 肝硬化患者SARS-CoV-2检测阳性率较低(8.5% vs 11.5%)。
  • 肝硬化合并感染者30天死亡率17.1%、通气率13.0%,高于其他组。
  • 肝硬化患者感染后机械通气风险增4.1倍、死亡风险增3.5倍。

核心结论

  • SARS-CoV-2感染使肝硬化患者死亡风险增加3.5倍。
  • 肝硬化使SARS-CoV-2感染患者死亡风险增加1.7倍。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人健康系统2020年3月1日至5月14日检测SARS-CoV-2的88,747例患者,随访至2020年6月22日。

主要发现

  • 30天死亡率和通气率从无肝硬化未感染组(2.3%和1.6%)逐步升至肝硬化未感染组(5.2%和3.6%)、无肝硬化感染组(10.6%和6.5%)和肝硬化感染组(17.1%和13.0%)。
  • 肝硬化患者中,感染者较未感染者机械通气风险aHR 4.12(95%CI 2.79-6.10)、死亡风险aHR 3.54(95%CI 2.55-4.90)。
  • 感染患者中,肝硬化者较无肝硬化者住院aHR 1.37(95%CI 1.12-1.66)、通气aHR 1.61(95%CI 1.05-2.46)、死亡aHR 1.65(95%CI 1.18-2.30)。
  • 肝硬化合并感染者死亡的最重要预测因素为高龄、肝硬化失代偿和高MELD评分。

关键数值与推荐

  • 肝硬化患者检测阳性率8.5% vs 无肝硬化11.5%,调整OR 0.83(95%CI 0.69-0.99)。
  • 肝硬化患者感染后机械通气aHR 4.12(95%CI 2.79-6.10),死亡aHR 3.54(95%CI 2.55-4.90)。
  • 感染患者中肝硬化住院aHR 1.37(95%CI 1.12-1.66)、通气aHR 1.61(95%CI 1.05-2.46)、死亡aHR 1.65(95%CI 1.18-2.30)。

临床怎么用

  • 肝硬化患者应重视SARS-CoV-2感染的预防,感染后需密切监测并积极干预以降低死亡风险。
  • 对高龄、失代偿或高MELD评分的肝硬化合并感染者应加强监护。

局限性

  • 研究基于美国退伍军人人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Whether patients with cirrhosis have increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the extent to which infection and cirrhosis increase the risk of adverse patient outcomes remain unclear. APPROACH AND RESULTS: We identified 88,747 patients tested for SARS-CoV-2 between March 1, 2020, and May 14, 2020, in the Veterans Affairs (VA) national health care system, including 75,315 with no cirrhosis-SARS-CoV-2-negative (C0-S0), 9,826 with no cirrhosis-SARS-CoV-2-positive (C0-S1), 3,301 with cirrhosis-SARS-CoV-2-negative (C1-S0), and 305 with cirrhosis-SARS-CoV-2-positive (C1-S1). Patients were followed through June 22, 2020. Hospitalization, mechanical ventilation, and death were modeled in time-to-event analyses using Cox proportional hazards regression. Patients with cirrhosis were less likely to test positive than patients without cirrhosis (8.5% vs. 11.5%; adjusted odds ratio, 0.83; 95% CI, 0.69-0.99). Thirty-day mortality and ventilation rates increased progressively from C0-S0 (2.3% and 1.6%) to C1-S0 (5.2% and 3.6%) to C0-S1 (10.6% and 6.5%) and to C1-S1 (17.1% and 13.0%). Among patients with cirrhosis, those who tested positive for SARS-CoV-2 were 4.1 times more likely to undergo mechanical ventilation (adjusted hazard ratio [aHR], 4.12; 95% CI, 2.79-6.10) and 3.5 times more likely to die (aHR, 3.54; 95% CI, 2.55-4.90) than those who tested negative. Among patients with SARS-CoV-2 infection, those with cirrhosis were more likely to be hospitalized (aHR, 1.37; 95% CI, 1.12-1.66), undergo ventilation (aHR, 1.61; 95% CI, 1.05-2.46) or die (aHR, 1.65; 95% CI, 1.18-2.30) than patients without cirrhosis. Among patients with cirrhosis and SARS-CoV-2 infection, the most important predictors of mortality were advanced age, cirrhosis decompensation, and high Model for End-Stage Liver Disease score. CONCLUSIONS: SARS-CoV-2 infection was associated with a 3.5-fold increase in mortality in patients with cirrhosis. Cirrhosis was associated with a 1.7-fold increase in mortality in patients with SARS-CoV-2 infection.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. Hepatology. 2021. PMID: 33219546. doi:10.1002/hep.31649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。